Market Cap 258.71B
Revenue (ttm) 104.18B
Net Income (ttm) 12.36B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.24
Profit Margin 11.87%
Debt to Equity Ratio 2.26
Volume 335,100
Avg Vol 620,482
Day's Range N/A - N/A
Shares Out 2.58B
Stochastic %K 45%
Beta 0.49
Analysts Sell
Price Target $103.90

Company Profile

Nestlé S.A., together with its subsidiaries, operates as a food and beverage company. It operates through Zone North America; Zone Europe; Zone Asia, Oceania and Africa; Zone Latin America; Zone Greater China; Nestlé Health Science; and Nespresso segments. The company offers water under the Acqua Panna, Nestlé Pure Life, Perrier, S.Pellegrino, Sanpellegrino, and other local brands; and chocolate and confectionery products under the Aero, Baci Perugina, KitKat, Milkybar, Smarties, and other local...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 41 21 924 1111
Address:
Avenue Nestlé 55, Vevey, Switzerland
I_am_Sparta
I_am_Sparta Oct. 27 at 10:32 AM
$MCRB see you at All Time Low..... $NSRGY never buy this 💩💩💩
0 · Reply
Hastamatr
Hastamatr Oct. 22 at 3:16 AM
$OTLY And connecting the dots , with my previous post about Goudet. JDE Peets ($JDEPY) merging with Keurig ($KDP) and beverages will be spinned off. From JAB website : “JAB works with three globally recognized Senior Advisors who provide advice on investments and various governance and strategy matters: Bertrand Badré, Olivier Goudet, and Antonio Weiss.“ Oatly investment (10% of the company) of Goudet through Platin SARL must be personal but JAB-aligned signal of strategic interest in especially within the coffee ecosystem that JAB is now re-consolidating via the Keurig / JDE Peet’s combination… So it will not be Nestle($NSRGY ) that I was always thinking about… It will be one of the JAB future companies to take it over in 2027/2028 after merger&spin off finalizes. And first stone laid… Don’t get surprised if he increases his position gradually… Wow, now all makes much better sense … Prepare for the ride guys…🤩
2 · Reply
wha1e
wha1e Oct. 16 at 9:33 PM
$NSRGY Analysts ratings: 11 Buys, 12 Holds, and 1 Sell with an average 12-month PT of 85 CHF (Swiss Franc)
0 · Reply
Okadarlan
Okadarlan Oct. 16 at 3:50 PM
$NSRGY lets gooo
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 16 at 2:23 PM
Nestle’s US-listed Shares Rally On Plans To Reduce 16,000 Global Jobs Over Two Years $NSRGY https://stocktwits.com/news/equity/markets/nestles-us-listed-shares-rally-on-plans-to-reduce-16-000-global-jobs/ch6p3LSR3np
0 · Reply
inspector_gadget86
inspector_gadget86 Oct. 16 at 8:07 AM
$NSRGY In a bid to improve operational efficiency, the firm said it will cut 12,000 white-collar jobs and a further 4,000 roles will be reduced over the next two years.
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 16 at 7:10 AM
Nestle To Cut Nearly 6% Roles To Save Costs: Retail Mood Bearish $NSRGY $XLP https://stocktwits.com/news/equity/markets/nestle-to-cut-nearly-6-roles-to-save-costs-retail-mood-bearish/ch6YHwlR3Vp
0 · Reply
Numbersandfacts
Numbersandfacts Sep. 29 at 3:39 PM
$MCRB Danone, one of Nestle $NSRGY rivals and competitors, has acquired the akkermansia company. They understand the microbiome is the future of food, medicines and supplements. If Nestle doesn't want Seres its patents and pipeline, I say the admin should reach out to Danone!
0 · Reply
SenefAS
SenefAS Sep. 24 at 11:31 AM
Canaccord raised the price target on Seres Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres’ proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions $MCRB $XBI $NSRGY
0 · Reply
Numbersandfacts
Numbersandfacts Sep. 18 at 3:20 PM
$MCRB Danone has bought the Akkermansia company. $NSRGY your move!
0 · Reply
Latest News on NSRGY
No data available.
I_am_Sparta
I_am_Sparta Oct. 27 at 10:32 AM
$MCRB see you at All Time Low..... $NSRGY never buy this 💩💩💩
0 · Reply
Hastamatr
Hastamatr Oct. 22 at 3:16 AM
$OTLY And connecting the dots , with my previous post about Goudet. JDE Peets ($JDEPY) merging with Keurig ($KDP) and beverages will be spinned off. From JAB website : “JAB works with three globally recognized Senior Advisors who provide advice on investments and various governance and strategy matters: Bertrand Badré, Olivier Goudet, and Antonio Weiss.“ Oatly investment (10% of the company) of Goudet through Platin SARL must be personal but JAB-aligned signal of strategic interest in especially within the coffee ecosystem that JAB is now re-consolidating via the Keurig / JDE Peet’s combination… So it will not be Nestle($NSRGY ) that I was always thinking about… It will be one of the JAB future companies to take it over in 2027/2028 after merger&spin off finalizes. And first stone laid… Don’t get surprised if he increases his position gradually… Wow, now all makes much better sense … Prepare for the ride guys…🤩
2 · Reply
wha1e
wha1e Oct. 16 at 9:33 PM
$NSRGY Analysts ratings: 11 Buys, 12 Holds, and 1 Sell with an average 12-month PT of 85 CHF (Swiss Franc)
0 · Reply
Okadarlan
Okadarlan Oct. 16 at 3:50 PM
$NSRGY lets gooo
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 16 at 2:23 PM
Nestle’s US-listed Shares Rally On Plans To Reduce 16,000 Global Jobs Over Two Years $NSRGY https://stocktwits.com/news/equity/markets/nestles-us-listed-shares-rally-on-plans-to-reduce-16-000-global-jobs/ch6p3LSR3np
0 · Reply
inspector_gadget86
inspector_gadget86 Oct. 16 at 8:07 AM
$NSRGY In a bid to improve operational efficiency, the firm said it will cut 12,000 white-collar jobs and a further 4,000 roles will be reduced over the next two years.
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 16 at 7:10 AM
Nestle To Cut Nearly 6% Roles To Save Costs: Retail Mood Bearish $NSRGY $XLP https://stocktwits.com/news/equity/markets/nestle-to-cut-nearly-6-roles-to-save-costs-retail-mood-bearish/ch6YHwlR3Vp
0 · Reply
Numbersandfacts
Numbersandfacts Sep. 29 at 3:39 PM
$MCRB Danone, one of Nestle $NSRGY rivals and competitors, has acquired the akkermansia company. They understand the microbiome is the future of food, medicines and supplements. If Nestle doesn't want Seres its patents and pipeline, I say the admin should reach out to Danone!
0 · Reply
SenefAS
SenefAS Sep. 24 at 11:31 AM
Canaccord raised the price target on Seres Therapeutics to $22 from $14 and keeps a Buy rating on the shares. The firm noted the FDA provided feedback on Seres’ proposed Phase 2 SER-155 study in bloodstream infections, which could aid in partnership discussions $MCRB $XBI $NSRGY
0 · Reply
Numbersandfacts
Numbersandfacts Sep. 18 at 3:20 PM
$MCRB Danone has bought the Akkermansia company. $NSRGY your move!
0 · Reply
StreetwiseReports
StreetwiseReports Sep. 16 at 8:34 PM
Change of CEO at Nestle With Stock Undervalued https://ow.ly/1JPt50WXNCt Global Analyst Adrian Day shares a brief update on developments at three companies on his list. $NESN $NSRGY $OGN.V $OGNNF $PAAS
0 · Reply
Thepark88
Thepark88 Sep. 16 at 11:31 AM
$LLY $MCRB $NSRGY $SGTX more similarities, same as poseida, sit tight
1 · Reply
SenefAS
SenefAS Sep. 16 at 9:59 AM
Did you see similarities ? 🚨 Before the buyout of Sigilon $SGTX a company owned by Flagship the same company behind Seres $MCRB There was a corporate split and the company was bought out a month later... $NSRGY $NESN.SW $LLY
0 · Reply
SenefAS
SenefAS Sep. 15 at 8:38 AM
$IBB $MCRB $NSRGY $XBI Soon the big announcement ? 📣
0 · Reply
SenefAS
SenefAS Sep. 13 at 4:21 AM
📊 What the chart shows: •Strong rally from ~$6.20 in early April to ~$17.40 by early September (+181%). 📊 Key insights from the chart: $MCRB : ◦April 2025: ~$6.20 → Early Sept 2025: ~$17.40 (+181%) ◦Spiked above $22 intraday after the Sept 5 Nestlé $41/share bid the Sept 5 Nestlé $41/share bid before settling lower. $NSRGY #biotech $XBI $IBB Outperformed the biotech sector dramatically. Trend phases: •Light green zone = sustained uptrend •Light gray zone = consolidation •Salmon zone = September spike on Nestlé news And you still not believe in the BO 🙃
0 · Reply
SenefAS
SenefAS Sep. 10 at 9:02 PM
Did you have see that all the game player in the food industry buy a microbiome company the last in date it’s Danone : https://www.danone.com/newsroom/press-releases/acquisition-of-the-akkermansia-company.html $MCRB $DANOY $NSRGY $UL
2 · Reply
SenefAS
SenefAS Sep. 10 at 7:34 PM
Whispers on Wall Street: Nestlé reportedly eyeing a $760M takeover of Seres Therapeutics $MCRB 💊 SER‑155: cutting infection risk by 77% in trials 🏆 Breakthrough Therapy status from the FDA 📈 Stock already surging on the chatter (300% in 3 month) If Nestlé pulls the trigger, this could be one of the biggest microbiome deals of the decade. #Biotech #MCRB #Nestle #Investing #FDA #M&A $NSRGY
0 · Reply
SenefAS
SenefAS Sep. 10 at 2:04 PM
$MCRB $NSRGY I just missed on this time line to mention on the board nomination of Dr Dr. Hans-Juergen Woerle the CMO of Nestle Health and yes of course still none nomination of a CMO at Seres… 😉
0 · Reply
SenefAS
SenefAS Sep. 9 at 4:20 PM
$IBB $MCRB $NSRGY $XBI Don’t Panic read this post and do your own DD…
1 · Reply
SenefAS
SenefAS Sep. 8 at 11:10 AM
I hope some analysts ask today about that offer: Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00 p.m. ET on September 8, 2025. $MCRB $NSRGY $XBI $IBB
1 · Reply
SenefAS
SenefAS Sep. 8 at 8:41 AM
Finally Seres Therapeutics received offers of Nestlé for 41$ + 35$ CVR reported by Swiss media @InsideParade & @awp_de that’s look not bad :) Probably the last time to buy more ? $MCRB $NSRGY #biotech $XBI $IBB
2 · Reply
SwissBull7
SwissBull7 Sep. 7 at 10:11 PM
$LKNCY & $NSRGY 5 Brand innovations leading the way at Nestlé Bernard Meunier Executive Vice President Head of Strategic Business Units and Marketing and Sales https://www.nestle.com/stories/brand-innovation-coffee-pet-food-leading
1 · Reply